Company news
Black Diamond Therapeutics, Inc. news in 2023
Black Diamond Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
December 12, 2023
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 5, 2023
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
October 13, 2023
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 3, 2023
Black Diamond Therapeutics Announces CEO Transition
September 17, 2023
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
September 10, 2023
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
June 28, 2023
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
June 27, 2023
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
June 26, 2023
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
June 12, 2023
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
June 1, 2023
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
April 17, 2023
Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting
April 16, 2023
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 8, 2023
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 26, 2023
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023